Open AccessPharmacogenetics of fluoxetine
Author(s) -
Maxim A. Novitsky,
Stanislav Skopin,
Vadim Kravtsov
Publication year - 2021
Publication title -
personalized psychiatry and neurology
Language(s) - English
Resource type - Journals
ISSN - 2712-9179
DOI - 10.52667/712-9179-2021-1-1-93-101
Subject(s) - fluoxetine , pharmacogenetics , medicine , serotonin transporter , reuptake , reuptake inhibitor , psychiatry , psychology , anxiety , pharmacology , serotonin , antidepressant , receptor , biology , genotype , genetics , gene
There is a number of antidepressants (ADs) which prevent reabsorption of neurotransmitters in the body. Known together as reuptake inhibitors, they prevent the reuptake of one or some neurotransmitters so that the majority of them is present and active in the brain. Selective serotonin reuptake inhibitors (SSRIs) work at the expense of specific inhibition of serotonin reuptake. Such new SSRIs fluoxetine (FXT), are effective for treatment of depressive disorders in most cases of schizophrenia. The effectiveness of SSRIs is not immediate; therefore, medication can take up to several weeks to be fully effective. FXT is one of the top ten prescribed antidepressants. FXT is prescribed in cases of depressive disorders in adults and adolescents [1], obsessive-compulsive and anxiety-depressive disorders [2], as well as for the therapy of bulimia nervosa [3]. Pharmacogenetic markers of FXT safety are being actively studied. Some pharmacogenetic markers of therapy safety have been established: genes of serotonin receptor isoforms and its transporters ( HTR1A, HTR1B, SCL6A4 ).